Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.61), $0.22 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $4.87 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.